R&D Trends

OrbiMed launches $307M Israel venture capital fund

Tuesday, May 24, 2016

OrbiMed, an investment firm focused on the healthcare sector, announced the closing of its second Israel-focused venture capital fund, OrbiMed Israel Partners II, LP, with approximately $307 million in capital commitments. Investors in the fund include several of the world’s largest healthcare companies, in addition to dozens of institutional investors and family offices.

[Read More]

Report: 2015 broke R&D records

Monday, May 23, 2016

The Biotechnology Innovation Organization (BIO) has released a new report, “Emerging Therapeutic Company Investment and Deal Trends,” highlighting 10 years (2006-2015) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers clinical pipeline snapshots to provide context on the degree of industry partnering and the contribution of emerging companies.

[Read More]

NIH funds new studies on the impact of genomic information

Tuesday, May 17, 2016

Four new grants from the National Institutes of Health will support research on the ethical, legal and social questions raised by advances in genomics research and the increasing availability of genomic information. The awards will fund researchers at interdisciplinary centers through the National Human Genome Research Institute’s (NHGRI) Centers of Excellence in Ethical, Legal and Social Implications Research (CEER) program.

[Read More]

Sanofi, Johns Hopkins partner on multiple sclerosis research

Monday, May 16, 2016

Sanofi Genzyme, the specialty care global business unit of Sanofi, has announced a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.

[Read More]

AVROBIO awarded Johnson & Johnson JLabs Incubator Space

Monday, May 16, 2016

AVROBIO, a clinical-stage biotechnology company developing transformative, life-changing gene therapies targeting rare diseases and cancer, has been awarded lab space at Johnson & Johnson’s (J&J) newest JLABS facility in Toronto, Ontario. AVROBIO, headquartered in Cambridge, Massachusetts, with researchers in Toronto, will join other early stage companies in the 40,000 square foot facility opening this spring.

[Read More]